CT26 is an N-nitroso-N-methylurethane-(NNMU) induced, undifferentiated colon carcinoma cell line. It was cloned to generate the cell line designated CT26.WT (ATCC CRL-2638). Use CT26.WT mouse fibroblasts with CT26.CL25 (ATCC CRL-2639) as a model for testing immunotherapy protocols and in studies on the host immune response.

2016年2月1日 · The CT26 model is highly responsive to anti-CTLA4 antibody treatment with 100% of treated mice showing tumor regressions.

Establishment of mouse colonic carcinoma cell lines with different metastatic properties.

The CT26 model is highly responsive to anti-CTLA4 antibody treatment with 100% of treated mice showing tumor regressions. In studies where we evaluate long term survival we find that about 70-90% of the treated mice will develop long term cures and that re-implantation of CT26 demonstrates primarily lack of tumor re-growth, suggesting the ...

2021年11月13日 · We performed in vivo screening for anti-PD-1 therapy across 23 syngeneic tumor models and found that CT-26 and Colon 26, which are murine colorectal carcinoma derived from BALB/c mice, showed different sensitivity to anti-PD-1.

In a syngeneic CT26 model, cancer cells from a particular mouse strain are implanted back into mice of the same strain, allowing researchers to study the interaction between the tumor and the immune system in a genetically matched system.

Here, we present an integrated map of the genome, transcriptome and immunome of an epithelial mouse tumor, the CT26 colon carcinoma cell line. We found that Kras is homozygously mutated at p.G12D, Apc and Tp53 are not mutated, and Cdkn2a is homozygously deleted.

The cell is a clone of the N-nitroso-N-methylrethane-induced undifferentiated CT26 colon carcinoma cell line. These cells are adherent and have a fibroblast morphology. They will form tumors and metastases post implantation into syngenic BALB/c mice …

Preclinically, the murine CT26 colon carcinoma line has become a platform model for evaluating the potential of drug combinations with immune checkpoint inhibitor antibodies. It is a highly immunogenic tumor and tends to show objective response rates to a number of commercially available checkpoint inhibitors.

Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. Highly metastatic variant of a mouse colon carcinoma cell line, LM17 and its response to GM-CSF gene therapy. Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma.